Alice P. Albright
Vorstandsvorsitzender bei Millennium Challenge Corp.
Profil
Alice P.
Albright is currently the Chief Executive Officer at Millennium Challenge Corp.
Prior to this, she was the Director-Emeritus at International AIDS Vaccine Initiative, Inc.
Aktive Positionen von Alice P. Albright
| Unternehmen | Position | Beginn |
|---|---|---|
| Millennium Challenge Corp. | Vorstandsvorsitzender | 01.02.2022 |
Ehemalige bekannte Positionen von Alice P. Albright
| Unternehmen | Position | Ende |
|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Direktor/Vorstandsmitglied | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
| Millennium Challenge Corp. | Government |
